Gareth Lingham

Gareth Lingham

Auto-generated profile, based on publicly available information

Gareth Lingham

Centre for Ophthalmology and Visual Science (incorporating Lions Eye Institute), University of Western Australia, Perth, Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Ophthalmology
Verified
Journal Article
Closed access
RGRobyn Guymer
Robyn Guymer
CMCaroline M. Markey
Caroline M. Markey
IMIan L. McAllister
Ian L. McAllister
MGMark C. Gillies
Mark C. Gillies
AHAlex P. Hunyor
Alex P. Hunyor
ZKZena Khalil
Zena Khalil

13 November 2019 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
GLGareth Lingham
Gareth Lingham
DMDavid A Mackey
David A Mackey
RLRobyn Lucas
Robyn Lucas
SYSeyhan Yazar
Seyhan Yazar
Myopia is an increasingly common condition that is associated with significant costs to individuals and society. Moreover, myopia is associated with increased risk of glaucoma, retinal detachment and myopic maculopathy, which in turn can lead to blindness. It is now well established that spending more time outdoors during childhood lowers the risk of developing myopia and may delay progression of myopia. There has been great interest in further exploring this relationship and exploiting it as a public health intervention aimed at preventing myopia in children. However, spending more time outdoors can have detrimental effects, such as increased risk of melanoma, cataract and pterygium. Understanding how spending more time outdoors prevents myopia could advance development of more targeted interventions for myopia. We reviewed the evidence for and against eight facets of spending time outdoors that may protect against myopia: brighter light, reduced peripheral defocus, higher vitamin D levels, differing chromatic spectrum of light, higher physical activity, entrained circadian rhythms, less near work and greater high spatial frequency (SF) energies. There is solid evidence that exposure to brighter light can reduce risk of myopia. Peripheral defocus is able to regulate eye growth but whether spending time outdoors substantially changes peripheral defocus patterns and how this could affect myopia risk is unclear. Spectrum of light, circadian rhythms and SF characteristics are plausible factors, but there is a lack of solid evidence from human studies. Vitamin D, physical activity and near work appear unlikely to mediate the relationship between time spent outdoors and myopia.

1 April 2021 in Ophthalmology
Verified
Journal Article
Closed access
ECElsie Chan
Elsie Chan
ECElaine W. Chong
Elaine W. Chong
GLGareth Lingham
Gareth Lingham
LSLouis J. Stevenson
Louis J. Stevenson
PSPaul G. Sanfilippo
Paul G. Sanfilippo
SYSeyhan Yazar
Seyhan Yazar

9 September 2022 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Open access
SLSamantha Sze‐Yee Lee
Samantha Sze‐Yee Lee
GLGareth Lingham
Gareth Lingham
MBMagdalena Blaszkowska
Magdalena Blaszkowska
PSPaul G. Sanfilippo
Paul G. Sanfilippo
AKAdrian Koay
Adrian Koay
DMDavid A. Mackey
David A. Mackey
Background: To test the hypothesis that 0.01% atropine eyedrops are a safe and effective myopia‐control approach in Australian children.Methods: Children (6–16 years; 49% Europeans, 18% East Asian, 22% South Asian, and 12% other/mixed ancestry) with documented myopia progression were enrolled into this single‐centre randomised, parallel, double‐masked, placebo‐controlled trial and randomised to receive 0.01% atropine (n = 104) or placebo (n = 49) eyedrops (2:1 ratio) instilled nightly over 24 months (mean index age = 12.2 ± 2.5 and 11.2 ± 2.8 years, respectively). Outcome measures were the changes in spherical equivalent (SE) and axial length (AL) from baseline.Results: At 12 months, the mean SE and AL change from baseline were −0.31D (95% confidence interval [CI] = −0.39 to −0.22) and 0.16 mm (95%CI = 0.13–0.20) in the atropine group and −0.53D (95%CI = −0.66 to −0.40) and 0.25 mm (95%CI = 0.20–0.30) in the placebo group (group difference p ≤ 0.01). At 24 months, the mean SE and AL change from baseline was −0.64D (95%CI = −0.73 to −0.56) and 0.34 mm (95%CI = 0.30–0.37) in the atropine group, and −0.78D (95%CI = −0.91 to −0.65) and 0.38 mm (95%CI = 0.33–0.43) in the placebo group. Group difference at 24 months was not statistically significant (p = 0.10). At 24 months, the atropine group had reduced accommodative amplitude and pupillary light response compared to the placebo group.Conclusions: In Australian children, 0.01% atropine eyedrops were safe, well‐tolerated, and had a modest myopia‐control effect, although there was an apparent decrease in efficacy between 18 and 24 months, which is likely driven by a higher dropout rate in the placebo group.

11 September 2023 in Acta Ophthalmologica
Verified
Journal Article
Open access
JLJames Loughman
James Loughman
EKEmmanuel Kobia‐Acquah
Emmanuel Kobia‐Acquah
GLGareth Lingham
Gareth Lingham
JBJohn Butler
John Butler
ELEkaterina Loskutova
Ekaterina Loskutova
DFDaniel Ian Flitcroft
Daniel Ian Flitcroft
Purpose: The Myopia Outcome Study of Atropine in Children (MOSAIC) is an investigator‐led, double‐masked, randomized controlled trial investigating the efficacy and safety of 0.01% atropine eye drops for managing myopia progression in a predominantly White, European population.Methods: Children aged 6–16 years with myopia were randomly allocated 2:1 to nightly 0.01% atropine or placebo eye drops in both eyes for 2 years. The primary outcome was cycloplegic spherical equivalent (SE) progression at 24 months. Secondary outcomes included axial length (AL) change, safety and acceptability. Linear mixed models with random intercepts were used for statistical analyses.Results: Of 250 participants enrolled, 204 (81.6%) completed the 24‐month visit (136 (81.4%) treatment, 68 (81.9%) placebo). Baseline characteristics, drop‐out and adverse event rates were similar between treatment and control groups. At 24 months, SE change was not significantly different between 0.01% atropine and placebo groups (effect = 0.10 D, p = 0.07), but AL growth was lower in the 0.01% atropine group, compared to the placebo group (−0.07 mm, p = 0.007). Significant treatment effects on SE (0.14 D, p = 0.049) and AL (−0.11 mm, p = 0.002) were observed in children of White, but not non‐White (SE = 0.05 D, p = 0.89; AL = 0.008 mm, p = 0.93), ethnicity at 24 months. A larger treatment effect was observed in subjects least affected by COVID‐19 restrictions (SE difference = 0.37 D, p = 0.005; AL difference = −0.17 mm, p = 0.001).Conclusions: Atropine 0.01% was safe, well‐tolerated and effective in slowing axial elongation in this European population. Treatment efficacy varied by ethnicity and eye colour, and potentially by degree of COVID‐19 public health restriction exposure during trial participation.

1 June 2020 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
SLSamantha S.Y. Lee
Samantha S.Y. Lee
GLGareth Lingham
Gareth Lingham
DADavid Alonso-Caneiro
David Alonso-Caneiro
FCFred Chen
Fred Chen
SYSeyhan Yazar
Seyhan Yazar
DMDavid A. Mackey
David A. Mackey